John D. Imig, PhD
- Pharmacology and Toxicology
BA, Biology, Blackburn College, 1985
The Imig laboratory is dedicated to understanding the mechanisms by which certain fatty acids “eicosanoids” influence kidney and cardiovascular function. Research in the laboratory focuses on kidney and blood vessel function in normal and disease states. We have developed novel eicosanoid-based drugs to treat diseases including hypertension, stroke, heart attacks, diabetes, and kidney diseases. These novel drugs have tremendous potential as a therapy for cardiovascular and kidney diseases.
Hypertension, Diabetes, & Metabolic Syndrome
Obesity, hypertension, and type 2 diabetes are major contributing factors to the increase in the number of patients that have cardiovascular events and end-organ damage. Metabolic syndrome is a serious health problem worldwide that has two major underlying causes, abdominal obesity and insulin resistance that clusters with other cardiovascular risk factors. Endothelial dysfunction, inflammation, oxidative stress, and insulin resistance are interrelated and increase the risk for cardiovascular events and end-organ damage in hypertension, diabetes, and metabolic syndrome. Moreover, eicosanoids are altered in these diseases and contribute to endothelial function, inflammation, oxidative stress, and insulin resistance. In particular, cyclooxygenase (COX), epoxygenase, and soluble epoxide hydrolase (sEH) metabolites are altered in disease states and contribute to the progression of disease processes. We have identified a distinct synergy between COX-2 and sEH inhibitors on the eicosanoid metabolome. This finding resulted in the development and synthesis of COX-2/sEH inhibitors that demonstrate great promise as a novel therapeutic approach for treating hypertension, diabetes, and metabolic syndrome. The goals of this project will identify novel ways to therapeutically target the eicosanoid metabolome for improving cardiovascular, renal, and pancreatic function in hypertension, diabetes, and metabolic syndrome.
Chronic Kidney Disease (CKD)
CKD from any cause is a serious public health problem; an estimated 33 million Americans have kidney disease. Hypertension, obesity, diabetes, infections, and genetic disease can lead to CKD. Other at risk groups include veterans and first-responders exposed to radiation, either on the battlefield, from terrorist events, or as a result of industrial accidents; these people risk developing radiation nephropathy and ultimately CKD. CKD also occurs in 15% of hematopoietic stem cell transplant (HSCT) patients, and has been clearly linked to irradiation at the time of the HSCT. HSCT is increasingly used worldwide for the treatment of cancer, and over 50,000 people per year now undergo HSCT. Long-term survival after HSCT is now near 50%, which means that more people will have late effects, which include CKD. CKD due to radiation also occurs after radionuclide therapy for cancer. Our laboratory has identified and developed epoxyeicosatrienoic acid (EET) analogs that show promise as a novel therapeutic approach for CKD. EET analogs have anti-inflammatory, anti-apoptotic, and anti-oxidative activities that will translate into a novel therapeutic for CKD. Consequently, we will test EET analogs as a new and better treatment for CKD.
Acute Kidney Injury (AKI)
Acute kidney injury (AKI), also known as, nephrotoxicity, occurs after exposure to drugs, other medical procedures, or exogenous toxins. The mortality rate for AKI patients is 30-60% and 20-30% of the survivors of AKI will develop CKD. There are limited options for treating AKI and these options currently include fluid and blood pressure management via drugs and intravenous fluids or hemodialysis. EETs have biological actions that implicate them as important contributors to kidney function. Over the past decade it has become increasingly apparent that EETs have a myriad of kidney actions and the overwhelming majority of these biological actions are kidney protective. Our innovation is based on the expected outcome that EET analogs have unique kidney actions that make them a novel target for developing treatments to prevent and treat AKI. Recent studies have demonstrated that EET analogs prevent AKI and renal damage that occurs with the anti-cancer drug cisplatin. This research project will identify novel ways to therapeutically target EETs for treating AKI.
(Imig JD.) Clin Sci (Lond). 2022 03 31;136(6):431-434 PMID: 35348182 PMCID: PMC8965847 SCOPUS ID: 2-s2.0-85127243330 03/30/2022
(Imig JD, Zhao X, Elmarakby AA, Pavlov T.) Frontiers in Physiology. 23 March 2022;13 SCOPUS ID: 2-s2.0-85128216167 03/23/2022
(Chiang KC, Rizk JG, Nelson DJ, Krishnamurti L, Subbian S, Imig JD, Khan I, Reddy ST, Gupta A.) Expert Opin Ther Targets. 2022 01;26(1):13-28 PMID: 35068281 SCOPUS ID: 2-s2.0-85125550339 01/25/2022
(Baranowska I, Gawrys O, Walkowska A, Olszynski KH, Červenka L, Falck JR, Adebesin AM, Imig JD, Kompanowska-Jezierska E.) Frontiers in Pharmacology. 17 January 2022;12 SCOPUS ID: 2-s2.0-85123754260 01/17/2022
(Imig JD, Cervenka L, Neckar J.) Biochemical Pharmacology. January 2022;195 SCOPUS ID: 2-s2.0-85120733144 01/01/2022
(Imig JD.) Advances in Pharmacology. 2022 SCOPUS ID: 2-s2.0-85127332294 01/01/2022
(Imig JD, Cervenka L, Neckar J.) Biochem Pharmacol. 2022 01;195:114866 PMID: 34863976 PMCID: PMC8712413 SCOPUS ID: 2-s2.0-85120733144 12/06/2021
(Chiang KC, Imig JD, Kalantar-Zadeh K, Gupta A.) Curr Opin Nephrol Hypertens. 2022 01 01;31(1):36-46 PMID: 34846312 SCOPUS ID: 2-s2.0-85122348632 12/01/2021
(Widiapradja A, Kasparian AO, McCaffrey SL, Kolb LL, Imig JD, Lacey JL, Melendez GC, Levick SP.) Cells. 2021 10 05;10(10) PMID: 34685639 PMCID: PMC8534147 SCOPUS ID: 2-s2.0-85116337891 10/24/2021
(Baranowska I, Gawrys O, Walkowska A, Olszynski KH, Červenka L, Falck JR, Adebesin AM, Imig JD, Kompanowska-Jezierska E.) Front Pharmacol. 2021;12:798642 PMID: 35111064 PMCID: PMC8802114 02/04/2022
(Jankiewicz WK, Barnett SD, Stavniichuk A, Hwang SH, Hammock BD, Belayet JB, Khan AH, Imig JD.) Front Pharmacol. 2021;12:744776 PMID: 34955823 PMCID: PMC8695932 12/28/2021
(Jankiewicz WK, Barnett SD, Stavniichuk A, Hwang SH, Hammock BD, Belayet JB, Khan AH, Imig JD.) Frontiers in Pharmacology. 9 December 2021;12 SCOPUS ID: 2-s2.0-85121640330 12/09/2021